Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results
25 Abril 2024 - 9:30AM
Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that
it will issue its fiscal 2024 fourth quarter and year-end earnings
release on Tuesday, May 14, 2024 after the market close. The
Company will host a conference call to discuss the results the
following morning, May 15th, at 8:30 a.m. ET.
The Company will provide a live Internet webcast as well as an
archived replay, which can be accessed from the Investor Relations
page of www.prestigeconsumerhealthcare.com. To participate via
phone, listeners calling from the U.S. and Canada may dial
800-715-9871 using the conference ID 4304270.
A conference call replay will be available for approximately one
week following completion of the live call and can be accessed on
the Company’s Investor Relations page.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is a leading consumer healthcare
products company with sales throughout the U.S. and Canada,
Australia, and in certain other international markets. The
Company’s diverse portfolio of brands include Monistat® and
Summer’s Eve® women's health products, BC® and Goody's® pain
relievers, Clear Eyes® and TheraTears® eye care products, DenTek®
specialty oral care products, Dramamine® motion sickness
treatments, Fleet® enemas and glycerin suppositories, Chloraseptic®
and Luden's® sore throat treatments and drops, Compound W® wart
treatments, Little Remedies® pediatric over-the-counter products,
Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment,
Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte®
rehydration products and the Fess® line of nasal and sinus care
products in Australia. Visit the Company's website at
www.prestigeconsumerhealthcare.com.
Note Regarding Forward-Looking Statements
This news release contains "forward-looking statements" within
the meaning of the federal securities laws that are intended to
qualify for the Safe Harbor from liability established by the
Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" generally can be identified by the use of
forward-looking terminology such as "outlook," "projected," "may,"
"will," "would," "expect," "anticipate," or "continue" (or the
negative or other derivatives of each of these terms) or similar
terminology. The "forward-looking statements" include, without
limitation, statements regarding the Company's future operating
results including revenues, organic growth, diluted earnings per
share, and free cash flow, the Company’s disciplined capital
deployment, and the Company’s ability to create shareholder value.
These statements are based on management’s estimates and
assumptions with respect to future events and financial performance
and are believed to be reasonable, though are inherently uncertain
and difficult to predict. Actual results could differ materially
from those expected as a result of a variety of factors, including
the impact of economic conditions, including as a result of labor
shortages, inflation and geopolitical instability, consumer trends,
the impact of the Company’s advertising and marketing and new
product development initiatives, customer inventory management
initiatives, fluctuating foreign exchange rates, competitive
pressures, and the ability of the Company’s manufacturing
operations and third party manufacturers and logistics providers
and suppliers to meet demand for its products and to avoid
inflationary cost increases and disruption as a result of labor
shortages. A discussion of other factors that could cause results
to vary is included in the Company’s Annual Report on Form 10-K for
the year ended March 31, 2023 and other periodic reports filed with
the Securities and Exchange Commission.
Investor Relations ContactPhil Terpolilli, CFA,
914-524-6819irinquiries@prestigebrands.com
Prestige Consumer Health... (NYSE:PBH)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Prestige Consumer Health... (NYSE:PBH)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024